Parkinson's Disease
Conditions
Brief summary
Parkinson's disease is the second most common neurodegenerative disease affecting about 1-3% of population above 60 years. Recently, non-motor symptoms are getting more attention in PD management. The pattern of PD onset and clinical course differ from one population to another. Many studies have been conducted to determine the clinical profile of PD in populations worldwide. However, no similar studies have been conducted in Egypt. Therefore, the investigators will conduct a nation-wide, collaborative, cross sectional study to determine the pattern of Parkinson's disease onset, clinical course, and non-motor symptoms among Egyptian population.
Interventions
None listed
Sponsors
Zagazig University
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients who meet the Parkinson's disease criteria of United Kingdom Brain Bank within the study centres.
Exclusion criteria
* Patients with vascular Parkinsonism (history of stroke) * Patients with treatment induced Parkinsonism * Patients with history of dopaminergic neurotoxin (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Age at disease onset | At enrolment | Patients age when the initial symptom appeared. |
| Time to diagnosis | At enrolment | Duration, in years, from appearance of initial symptom to receiving Parkinson's disease diagnosis. |
| Initial motor symptom | At enrolment | Number of patients with each initial motor symptom (tremor, rigidity, or bradykinesia). |
| Side of initial motor symptoms | At enrolment | Number of patients with either right or left side initial motor symptoms. |
| Clinical subtype of the disease | At enrolment | Number patients with each disease subtype (tremor dominant Parkinson's disease, hypokinetic-rigid dominant Parkinson's disease, or postural instability and gait disturbance dominant Parkinson's disease). |
| Duration of levodopa treatment from disease onset | At enrolment | Number of years on levodopa treatment since receiving parkinson's disease diagnosis |
| Levodopa equivalent dose | At enrolment | Current dose of levodopa per day |
| Non-motor symptoms | At enrolment | Non-motor symptoms measured by the non-motor symptoms questionnaire (NMS) |
| Quality of life | At enrolment | Mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort assessed by the parkinson's disease quality of life questionnaire (PDQ-39). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Stage of the disease [optional] | At enrolment | The stage of the disease (stage 1, stage 2, stage 3, or stage 4) according to Hoehn and Yahr classification. |
| Motor Functions [optional] | At enrolment | Motor functions assessed by the third part of the unified parkinson's disease rating scale (UPDRS III). |
Countries
Egypt
Contacts
Primary ContactAhmed S Negida
Outcome results
None listed